Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2545studies indexed1158with human data159registered trials2232carry a numeric findingLibrarian added 0 studies today
Showing 2 studiesSortNewest indexed ▾
A
grade
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.
Ribupatide · Diabetes, obesity & metabolism · 2023 · RCT · Phase 1 · n=90High-impact journal
Ribupatide showed a favorable safety profile and significant weight loss in a small Phase 1 trial, but further studies are needed to confirm these effects in larger populations.
Mean weight change in ribupatide groups ranged from -4.3 kg (-6.7%) to -7.7 kg (-9.6%), compared with -1.2 kg (-1.4%) in the placebo group.
D
grade
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.
Ribupatide · Diabetes, obesity & metabolism · 2026 · RCTHigh-impact journal
Ribupatide demonstrated a favorable safety profile and weight loss in a small Phase 1 trial, but further studies are needed to confirm its clinical efficacy.
Mean weight change in ribupatide groups ranged from -4.3 kg (-6.7%) to -7.7 kg (-9.6%) after four weekly doses, compared with -1.2 kg (-1.4%) in the placebo group.
Showing 2 of 2